Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Liver Transplantation
NCT03770130Phase 1Completed
- Sponsor
- Renji Hospital
- Start
- Jan 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine in Early allograft dysfunction (EAD) (2 arms), sponsored by Renji Hospital. Primary endpoint: Incidence of early allograft dysfunction at 7 days. Started Jan 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
Early allograft dysfunction (EAD)
Beyond the preview
Go deeper on NCT03770130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770130.